FDA Grants Priority Review to Huntington Disease Gene Therapy BLA

FDA accepted uniQure's biologics license application for the Huntington disease gene therapy ifezuntirgene inilparvovec and granted it Priority Review with a target action date of May 1, 2027, under the accelerated approval pathway.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Nov 2026 and 3 Nov 2026.